Sells LUPKYNIS, an oral treatment for adults with active lupus nephritis, to specialty pharmacies, a specialty distributor and a pharmaceutical partner, and develops aritinercept for autoimmune diseases.
10-K for FY2025, filed Feb 26, 2026Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical…View ↗
Aurinia sells LUPKYNIS to two specialty pharmacies and a specialty distributor in the United States (“U.S.”), and Aurinia sells LUPKYNIS…View ↗
In January 2021, the Company introduced LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active LN.…View ↗
Aritinercept is a dual inhibitor of B cell-activating factor (“BAFF”) and a proliferation-inducing ligand (“APRIL”) for the potential…View ↗
Aurinia sells LUPKYNIS to specialty pharmacies, a distributor and Otsuka; product sales are paid after delivery under standard customer credit terms. Its Otsuka deal also brings an upfront license fee, milestone payments, royalties as partner sales occur, and payment for product supply and manufacturing services.
10-K for FY2025, filed Feb 26, 2026The Company sells LUPKYNIS to two specialty pharmacies and a specialty distributor in the U.S., and the Company sells LUPKYNIS inventory to…View ↗
Revenue from product sales is recognized when the customer obtains control of the Company's product, which typically occurs on delivery.…View ↗
The Company’s major customers, which include two specialty pharmacies and its collaboration partner, Otsuka Pharmaceutical Co., Ltd…View ↗
The Company enters into out-license agreements with counterparties to develop and commercialize LUPKYNIS in certain ex-U.S. territories in…View ↗
At the inception of each arrangement that includes commercial sales milestone payments, the Company evaluates whether achieving each…View ↗
For arrangements that include sales-based royalties, revenue is recognized when the underlying product sales have occurred. Revenue is…View ↗
10-K for FY2025, filed Feb 26, 2026
FY2025 revenue by product or service ↗$283.1M
10-K for FY2025, filed Feb 26, 2026
$283.1M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Net product sales
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
96%
FY2022: 77%
|
Net product sales, FY2025
$271.3M Sources
|
Sold outright |
|
License, collaboration and royalty revenue
|
4.1%
FY2022: 23%
|
License, collaboration and royalty revenue, FY2025
$11.7M Sources
|
Aurinia sells LUPKYNIS to U.S. specialty pharmacies and a specialty distributor; Otsuka buys inventory for European and Japanese markets, where it markets the drug.
10-K for FY2025, filed Feb 26, 2026
Yes. Its net income in FY2025 was larger than its revenue and turned 48 cents into free cash flow.
10-Q for Q3 FY2026, filed Oct 30, 2026
Open tableView ↗
8-K, filed Aug 6, 2026
Aurinia reiterates its guidance for 2026 total revenue of $315 million to $325 million, up 11% to 15% compared to 2025, and 2026 net…View ↗
8-K, filed May 11, 2026
Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, on May 8, 2026, Parent completed a tender offer…View ↗
8-K, filed Apr 3, 2026
On March 30, 2026, Aurinia Pharma U.S., Inc., a Delaware corporation (“Parent”), entered into an Agreement and Plan of Merger (the “Merger…View ↗
8-K, filed Mar 23, 2026
Effective March 23, 2026, the Board of Directors of Aurinia Pharmaceuticals Inc. (“Aurinia”) appointed Kevin Tang as Aurinia’s Chief…View ↗
Growing. Revenue grew 6.2x in 4 years, from $45.6M in FY2021 to $283.1M in FY2025, about 58% a year.
Narrower stated disease focus
The older report described a broader focus spanning autoimmune, kidney and rare diseases; the latest describes LUPKYNIS for lupus nephritis and aritinercept for autoimmune diseases.
10-K for FY2022, filed Feb 28, 2023
Competes with GSK and Genentech
10-K for FY2025, filed Feb 26, 2026The pharmaceutical industry is competitive. While LUPKYNIS is the only FDA-approved oral therapy for the treatment of adult patients with…View ↗
Loading...